There are 2867 resources available
1027P - 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
Presenter: Claire Verschraegen
Session: Poster session 14
1028P - BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
Presenter: Rieke Fischer
Session: Poster session 14
1029P - Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: An open-label, multi-center phase II trial
Presenter: Yuanyuan Zhao
Session: Poster session 14
1032P - ML41256: Phase II study of atezolizumab (atezo) in combination with bevacizumab (beva) in advanced non-squamous non-small cell lung cancer (nsqNSCLC) patients (pts) pretreated with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs)
Presenter: Wen Feng Fang
Session: Poster session 14
1034P - A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EFGR-TKIs
Presenter: Caicun Zhou
Session: Poster session 14
1035P - A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)
Presenter: Chantal Decroisette
Session: Poster session 14
1036P - Anlotinib plus docetaxel vs. docetaxel as 2nd-line treatment of advanced non-small cell lung cancer (NSCLC): Updated results from ALTER-L016
Presenter: Yong Fang
Session: Poster session 14